Organogenesis Holdings Inc.
investors.organogenesis.comWhat Do They Do?
Sells regenerative medicine products for chronic and acute wounds and surgical and sports medicine applications to hospitals, wound care centers, surgery centers, and physician offices.
10-K for FY2025, filed Feb 26, 2026Organogenesis is a leading regenerative medicine company focused on empowering healing through the development, manufacturing, and sale of…View ↗
Our mission is advancing healing and recovery beyond expectations. Several of our existing and pipeline products in our portfolio have…View ↗
In the Advanced Wound Care market, we focus on the development and commercialization of products for the treatment of chronic and acute…View ↗
In the Surgical & Sports Medicine market, we are leveraging our broad regenerative medicine capabilities to address chronic and acute…View ↗
How Do They Make Money?
Customers pay for wound-care and surgical and sports medicine products at shipment, on the procedure date, or at delivery, depending on the contract.
10-K for FY2025, filed Feb 26, 2026The Company generates product revenue through the sale of Advanced Wound Care and Surgical & Sports Medicine products. There is a single…View ↗
-
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗
$564.2M
-
10-K for FY2025, filed Feb 26, 2026
$564.2M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net product revenue
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
100% |
Net product revenue, FY2025
$563M Sources
|
Sold outright |
|
Grant income
|
0.2% |
Grant income, FY2025
$1.1M Sources
|
Who Are Their Customers?
Health care facilities and clinicians—including hospitals, wound care centers, government facilities, surgery centers and physician offices—buy its products. In the U.S., advanced wound care products are sold through a direct sales force, while surgical and sports medicine products use direct representatives and independent agencies; overseas, sales use direct representatives in Switzerland and independent agents in Saudi Arabia and Kuwait.
10-K for FY2025, filed Feb 26, 2026Our mission is advancing healing and recovery beyond expectations. Several of our existing and pipeline products in our portfolio have…View ↗
Our current Advanced Wound Care portfolio is sold throughout the United States via an experienced direct sales force. We use a mix of…View ↗
Sales generated by our direct sales forces in the United States have represented, and we anticipate will continue to represent, a majority…View ↗
Do Revenues Turn Into Profits?
Yes. It kept 7 cents of every revenue dollar as net income in FY2025, but spent more cash than it brought in: free cash flow was −$24.5M.
10-K for FY2025, filed Feb 26, 2026
$44.7MView ↗
10-K for FY2025, filed Feb 26, 2026
$37MView ↗
10-K for FY2025, filed Feb 26, 2026
−$24.5MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$96.3MView ↗
- ▲ +925% (Loss)
- vs −$9.4M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 6, 2026
Open tableView ↗
Growing. Revenue grew 21% in 4 years, from $467.4M in FY2021 to $564.2M in FY2025, about 5% a year.
Broader wound-care lineup
The latest report lists additional wound-care products, including CYGNUS Dual, VIA Matrix and SimpliMax, beyond the products named in the older report.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 26, 2026In the Advanced Wound Care market, we focus on the development and commercialization of advanced wound care products for the treatment of…View ↗
In the Advanced Wound Care market, we focus on the development and commercialization of products for the treatment of chronic and acute…View ↗
Loading...
